Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Lung Injury

Interventions

DRUG

Lanadelumab

Monoclonal antibody that targets active plasma kallikrein

OTHER

Saline control

Trial Locations (1)

St Vincent's Hospital Melbourne, Melbourne

All Listed Sponsors

lead

St Vincent's Institute of Medical Research

OTHER

NCT04848272 - Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury | Biotech Hunter | Biotech Hunter